We can’t show the full text here under this license. Use the link below to read it at the source.
PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies
Blocking PD-1/PD-L1 Immune Checkpoints in Breast Cancer: Research Findings and Ways to Improve Response
AI simplified
Abstract
The effectiveness of immunotherapy may depend on tumor-intrinsic factors and cell interactions within the tumor microenvironment.
- Combining PD-1/PD-L1 immune checkpoint blockade with chemotherapy has shown promising efficacy in early and metastatic triple-negative breast cancer.
- Only a subset of patients experiences durable responses to this treatment.
- Identifying responders is critical for optimizing immune drug selection.
- Key findings from clinical trials indicate that the regulation of PD-L1 expression is influenced by various mechanisms.
- Recent advances suggest that ' quantity, type, and spatial arrangement could serve as promising biomarkers for therapy.
- Strategies to enhance the effectiveness of immune checkpoint blockers are being explored to support personalized treatment approaches.
AI simplified
Key numbers
64.8%
Pathologic Complete Remission Rate Increase
KEYNOTE-522 trial results for early-stage TNBC patients.
15 to 60%
Response Rate Range
Response rates for ICBs in breast cancer.
≥ 5%
TIL Level Predictive Threshold
Threshold identified in a randomized trial for TIL levels.